Featured this week:
- Hdac1 as an early determinant of intermediate-exhausted CD8+ T cell fate in chronic viral infection. Hu W, Shawn Hu S, Zhu S, Peng W, Badovinac VP, Zang C, Zhao X, Xue HH. Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2502256122. doi: 10.1073/pnas.2502256122. Epub 2025 May 7. PMID: 40333757
- In situ treatment with a TLR9 agonist virus-like particle to promote immune responses against oral epithelial dysplasia progression. Xu Y, Mcmillan A, Gupta N, Lemke-Miltner CD, Rataan AO, Areecheewakul S, Bhat DS, Lanzel EA, Geary SM, Simons AL, Weiner GJ, Salem AK. Cancer Immunol Immunother. 2025 May 3;74(6):189. doi: 10.1007/s00262-025-04023-1. PMID: 40317310
- Sumoylated Etv1 establishes mouse mammary cancer stem cells that support tumorigenesis by non-stem cancer cells. Li Z, Koch KE, Thompson DT, Van der Heide DM, Chang J, Franke CM, Suraju MO, Beck AC, Lorenzen AW, White JR, Bartschat NI, Kulak MV, Meyerholz DK, Kenny C, Weigel RJ. Dev Cell. 2025 Apr 25:S1534-5807(25)00207-2. doi: 10.1016/j.devcel.2025.04.005. Online ahead of print. PMID: 40315856